Although JACOB did not meet its primary endpoint, the study continues to demonstrate some, albeit limited, evidence of treatment activity and an acceptable safety profile for pertuzumab plus trastuzumab and chemotherapy in previously untreated HER2-positive metastatic GC/GEJC after long-term follow-up (≥ 44.4 months). Here, ERBB2 is linked to gastric cancer.